Jean F. Holloway Sells 472 Shares of Artivion, Inc. (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway sold 472 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $25.29, for a total value of $11,936.88. Following the sale, the senior vice president now directly owns 172,743 shares in the company, valued at approximately $4,368,670.47. This trade represents a 0.27 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Artivion Price Performance

Artivion stock opened at $24.22 on Friday. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $1.02 billion, a PE ratio of -1,211.00 and a beta of 1.79. Artivion, Inc. has a 12 month low of $19.11 and a 12 month high of $32.33. The stock has a 50-day moving average price of $29.13 and a two-hundred day moving average price of $27.79.

Artivion (NYSE:AORT) last posted its earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.51). The firm had revenue of $97.31 million during the quarter, compared to the consensus estimate of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. Analysts expect that Artivion, Inc. will post 0.37 EPS for the current year.

Hedge Funds Weigh In On Artivion

Several large investors have recently bought and sold shares of the company. Wellington Management Group LLP raised its position in Artivion by 2.9% in the third quarter. Wellington Management Group LLP now owns 1,656,264 shares of the company’s stock valued at $44,090,000 after purchasing an additional 46,267 shares during the last quarter. Wasatch Advisors LP raised its position in Artivion by 27.7% in the fourth quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company’s stock valued at $29,791,000 after purchasing an additional 226,160 shares during the last quarter. Next Century Growth Investors LLC raised its position in Artivion by 29.7% in the fourth quarter. Next Century Growth Investors LLC now owns 492,653 shares of the company’s stock valued at $14,085,000 after purchasing an additional 112,918 shares during the last quarter. Northern Trust Corp raised its position in shares of Artivion by 10.0% during the fourth quarter. Northern Trust Corp now owns 463,250 shares of the company’s stock worth $13,244,000 after acquiring an additional 42,170 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Artivion by 2.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 358,192 shares of the company’s stock worth $10,241,000 after acquiring an additional 8,343 shares during the last quarter. 86.37% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on AORT. JMP Securities reissued a “market outperform” rating and set a $33.00 target price on shares of Artivion in a report on Tuesday, December 10th. Stifel Nicolaus reduced their price objective on Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, February 25th. Oppenheimer raised their price objective on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Finally, Needham & Company LLC reduced their price objective on Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Artivion has a consensus rating of “Buy” and an average price target of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.